首页> 外文期刊>World Journal of Gastroenterology >Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma
【24h】

Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma

机译:失代偿性肝硬化肝细胞癌患者经导管动脉化疗栓塞,腹腔镜射频消融和保守治疗的比较

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To compare the therapeutic effect of transcatheter arterial chemoembolization (TACE), laparoscopic radiofrequency ablation (LRFA), and conservative treatment for the therapy of decompensated liver cirrhosis patients with hepatocellular carcinomas (HCC). METHODS: Between October 2000 and July 2003, one hundred patients with histologically proven primary HCC and clinical decompensated liver cirrhosis (Child classification B or C) were included in this study. Forty patients received LRFA (LRFA group), twenty received TACE (TACE group), and forty received conservative treatment (control group). We compared the survival, recurrence, and complication rates in these three groups, making adjustment using the tumor metastastic node staging system. RESULTS: The major complication rate in the TACE group (9/20) was significantly higher than that in the LRFA group (7/40). For patients with TMN stage II HCC, the survival rate of the LRFA group was better than that of the TACE and control groups (P=0.003) but the recurrence rates befween the LRFA and TACE groups did not differ. CONCLUSION: The LRFA group of patients had better clinical outcomes in terms of survival and complication rates in comparison with the TACE group or conservative treatment in patients with decompensated liver cirrhosis, especially in TMN patients with stage II HCC. LRFA is thus an appropriate alternative treatment for poor liver function among patients with HCC.
机译:目的:比较经导管动脉化疗栓塞(TACE),腹腔镜射频消融(LRFA)和保守治疗对失代偿性肝硬化肝细胞癌(HCC)的治疗效果。方法:在2000年10月至2003年7月之间,本研究包括了100例经组织学证实的原发性HCC和临床失代偿性肝硬化(儿童B级或C级)的患者。四十例接受LRFA治疗(LRFA组),二十例接受TACE治疗(TACE组),四十例接受保守治疗(对照组)。我们比较了这三组的生存率,复发率和并发症发生率,并使用肿瘤转移淋巴结分期系统进行了调整。结果:TACE组的主要并发症发生率(9/20)显着高于LRFA组(7/40)。对于TMN II期HCC患者,LRFA组的生存率优于TACE和对照组(P = 0.003),但LRFA和TACE组之间的复发率没有差异。结论:对于失代偿性肝硬化患者,特别是在TMN II期HCC患者中,与TACE组或保守治疗相比,LRFA组的患者在生存率和并发症发生率方面具有更好的临床结局。因此,LRFA是肝癌患者肝功能不佳的合适替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号